Drugs / RZ-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06695026 | Dec 2024 → Aug 2027 expected | hepatocellular carcinoma | Rznomics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06102525 | Oct 2024 → Mar 2029 expected | glioblastoma | Rznomics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05595473 | Jul 2022 → Mar 2029 expected | hepatocellular carcinoma | Rznomics, Inc. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06676891 | — | glioblastoma | Rznomics, Inc. | Available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RZ-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05595473 ↗ |
| Route | Other | “single intracerebral injection of RZ-001” NCT06676891 ↗ |